MedPath

Dayvigo

Brand Name: Dayvigo

Generic Name: Lemborexant

Active
Registration Number

DR-XY47690

Dosage Form

Film-Coated Tablet

Issuance Date

January 28, 2022

Expiry Date

January 28, 2027

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength5mg
PackagingAlu/PVC Blister Pack x 14's (Box of 28's)

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Orexin Receptor Antagonist
A
Application
Monitored Release
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

LemborexantActive
Monograph: Lemborexant

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform